Cargando…

Tislelizumab for cervical cancer: A retrospective study and analysis of correlative blood biomarkers

BACKGROUND: Tislelizumab is an anti-programmed cell death 1 (PD-1) monoclonal antibody engineered to minimize binding to Fcγ receptors. It has been used to treat several solid tumors. However, its efficacy and toxicity, and the predictive and prognostic value of baseline hematological parameters in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zheng, Xiaojing, Gu, Haifeng, Cao, Xinping, Pan, Baoyue, Xiang, Huiling, Ju, Mingxiu, Xu, Shijie, Zheng, Min
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9975598/ https://www.ncbi.nlm.nih.gov/pubmed/36875089 http://dx.doi.org/10.3389/fimmu.2023.1113369

Ejemplares similares

A Nomogram for Preoperative Prediction of the Risk of Lymph Node Metastasis in Patients with Epithelial Ovarian Cancer
por: Xiang, Huiling, et al.
Publicado: (2023)

Pretreatment Systemic Immune-Inflammation Index Can Predict Response to Neoadjuvant Chemotherapy in Cervical Cancer at Stages IB2-IIB
por: Liu, Pingping, et al.
Publicado: (2022)

Methyltransferase‐like 3 promotes cervical cancer metastasis by enhancing cathepsin L mRNA stability in an N6‐methyladenosine‐dependent manner
por: Liu, Pingping, et al.
Publicado: (2023)

Impact of the initial site of metastases on post-recurrence survival for neuroendocrine cervical cancer
por: Pan, Baoyue, et al.
Publicado: (2022)

Case Report: Life-threatening pancytopenia with tislelizumab followed by cerebral infarction in a patient with lung adenocarcinoma
por: Gu, Hang-Yu, et al.
Publicado: (2023)

Pretreatment C-Reactive Protein/Albumin Ratio is Associated With Poor Survival in Patients With 2018 FIGO Stage IB-IIA HPV-Positive Cervical Cancer
por: Jiang, Yinan, et al.
Publicado: (2021)

Case Report: THSD7A-Positive Membranous Nephropathy Caused by Tislelizumab in a Lung Cancer Patient
por: Chen, Minjiang, et al.
Publicado: (2021)

Neoadjuvant tislelizumab combined with chemotherapy in locally advanced oral or oropharyngeal squamous cell carcinoma: a real−world retrospective study
por: Wu, Wen-Jie, et al.
Publicado: (2023)

Case Report: Successful Management of a Refractory Plasmablastic Lymphoma Patient With Tislelizumab and Lenalidomide
por: Cheng, Lili, et al.
Publicado: (2021)

Case Report: Clinical Responses to Tislelizumab as a First-Line Therapy for Primary Hepatocellular Carcinoma With B-Cell Indolent Lymphoma
por: Li, Qijun, et al.
Publicado: (2021)

The MYBL2–CCL2 axis promotes tumor progression and resistance to anti-PD-1 therapy in ovarian cancer by inducing immunosuppressive macrophages
por: Pan, Baoyue, et al.
Publicado: (2023)

Tumor Flare Reaction in a Classic Hodgkin Lymphoma Patient Treated With Brentuximab Vedotin and Tislelizumab: A Case Report
por: Zhu, Chunting, et al.
Publicado: (2022)

Case Report: Complete response after tislelizumab treatment in a hepatocellular carcinoma patient with abdominal lymph node metastasis
por: Deng, Haihui, et al.
Publicado: (2023)

Tislelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma: 3-Year Follow-up and Correlative Biomarker Analysis
por: Song, Yuqin, et al.
Publicado: (2022)

Pathological complete response to neoadjuvant tislelizumab plus chemotherapy in stage IIIB small cell lung cancer: A case report and literature review
por: Zhou, Nan, et al.
Publicado: (2023)

Case report: Preliminary response to tislelizumab plus S-1 in patients with metastatic gallbladder carcinoma: A report of five cases and a literature review
por: Zhang, Yuzhu, et al.
Publicado: (2023)

Immune-related adverse events with severe pain and ureteral expansion as the main manifestations: a case report of tislelizumab-induced ureteritis/cystitis and review of the literature
por: Zhou, Qihao, et al.
Publicado: (2023)

Tislelizumab Plus Chemotherapy Sequential Neoadjuvant Therapy for Non-cCR Patients After Neoadjuvant Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma (ETNT): An Exploratory Study
por: He, Wenwu, et al.
Publicado: (2022)

Safety and efficacy of tislelizumab plus chemotherapy versus chemotherapy alone as neoadjuvant treatment for patients with locally advanced gastric cancer: real-world experience with a consecutive patient cohort
por: Jiang, Qi, et al.
Publicado: (2023)

Follistatin-Like 3 Correlates With Lymph Node Metastasis and Serves as a Biomarker of Extracellular Matrix Remodeling in Colorectal Cancer
por: Yang, Chao, et al.
Publicado: (2021)

LDL receptor related protein 1 is an adverse prognostic biomarker that correlates with stromal remodeling and macrophages infiltration in bladder cancer
por: Du, YiHeng, et al.
Publicado: (2023)

The Efficacy and Safety of Tislelizumab as Adjuvant Treatment for Advanced or Metastatic Bladder Cancer in People Living With HIV: A Retrospective Multi-Center Study
por: Wu, Menghua, et al.
Publicado: (2023)

Mining of immunological and prognostic-related biomarker for cervical cancer based on immune cell signatures
por: Wang, Nana, et al.
Publicado: (2022)

LAYN Is a Prognostic Biomarker and Correlated With Immune Infiltrates in Gastric and Colon Cancers
por: Pan, Jing-hua, et al.
Publicado: (2019)

Potent Neutralizing Humanized Antibody With Topical Therapeutic Potential Against HPV18-Related Cervical Cancer
por: Huang, Bilian, et al.
Publicado: (2021)

FUCA2 Is a Prognostic Biomarker and Correlated With an Immunosuppressive Microenvironment in Pan-Cancer
por: Zhong, Anyuan, et al.
Publicado: (2021)

DDOST Correlated with Malignancies and Immune Microenvironment in Gliomas
por: Chang, Xiaojing, et al.
Publicado: (2022)

The Effects of Axitinib plus Tislelizumab in the Treatment of Advanced Renal Cell Carcinoma
por: Wang, Zhixin, et al.
Publicado: (2022)

Tislelizumab-related enteritis successfully treated with adalimumab: A case report
por: Chen, Na, et al.
Publicado: (2022)

Tislelizumab combined with anlotinib in the second-line treatment of malignant pleural mesothelioma
por: Zhang, Dandan, et al.
Publicado: (2022)

Severe thyrotoxicosis induced by tislelizumab: a case report and literature review
por: Huo, Liman, et al.
Publicado: (2023)

Model‐based population pharmacokinetic analysis of tislelizumab in patients with advanced tumors
por: Budha, Nageshwar, et al.
Publicado: (2022)

Conversion therapy for advanced penile cancer with tislelizumab combined with chemotherapy: A case report and review of literature
por: Long, Xiang-Yu, et al.
Publicado: (2022)

Case report: Gemcitabine intravesical hyperthermic infusion combined with tislelizumab in muscle invasive bladder urothelium carcinoma
por: Du, Zheng, et al.
Publicado: (2022)

Tislelizumab in combination with gemcitabine plus cisplatin chemotherapy as first-line adjuvant treatment for locally advanced or metastatic bladder cancer: a retrospective study
por: Ren, Xiang, et al.
Publicado: (2022)

PTP4A3 Is a Prognostic Biomarker Correlated With Immune Infiltrates in Papillary Renal Cell Carcinoma
por: Song, Qian, et al.
Publicado: (2021)

The anti-PD-1 era of cervical cancer: achievement, opportunity, and challenge
por: Li, Chen, et al.
Publicado: (2023)

Analysis of macular structure in age-related cataract patients with different antibody levels of severe acute respiratory syndrome coronavirus-2 vaccine
por: Li, Xiaochun, et al.
Publicado: (2022)

Follicle-like tertiary lymphoid structures: A potential biomarker for prognosis and immunotherapy response in patients with laryngeal squamous cell carcinoma
por: Liang, Haifeng, et al.
Publicado: (2023)

The identification and validation of EphA7 hypermethylation, a novel biomarker, in cervical cancer
por: Zhang, Wenfan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mak0s912ddnmoq1ajuglsl8hjj